Latest research on Desvenlafaxine

Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin-norepinephrine reuptake inhibitor (SNRI class). Desvenlafaxine may be used to treat major depressive disorder and is being studied for use in the management of vasomotor symptoms in postmenopausal women. It is formulated as an extended release tablet. FDA approved in 2008.

Latest findings

Notably, the superiority of Desvenlafaxine over placebo on functioning was better observed in more severely ill patients. [source, 2016]
For instance, the superiority of Desvenlafaxine was not observed in the whole sample (P=0.067) but observed in the subgroup of more severely ill patients with MDD (P=0.017) in a 12-week RCT. [source, 2016]
The efficacy and the tolerability of Escitalopram, aSSRI and Desvenlafaxine, a non-selective SRI has been well-established. [source, 2016]
Thus, there are very limited studies available directly comparing efficacies of Escitalopram with Desvenlafaxine in treatment of major depression. [source, 2016]
Hence, a preliminary 1-year prospective randomized open label trial comparing efficacy and safety of Escitalopram with Desvenlafaxine in the treatment of major depression was undertaken. [source, 2016]
Patients meeting eligibility criteria at the screening visit were assigned randomly in 1:1 ratio to either receive Escitalopram or Desvenlafaxine. [source, 2016]
Dose of Desvenlafaxine in the first 3 weeks was 50 mg/day and 100 mg/day for the next 3 weeks. [source, 2016]
Both Escitalopram as well as Desvenlafaxine significantly (P < 0.001) reduced HAM-D, HAM-A, and CGI scores from their respective base lines [Table 2]. [source, 2016]
Patients who had received treatment with Venlafaxine or DesVenlafaxine in the past; a history of personality disorder or mental retardation, substance abuse, psychotic disorders, dementia, obsessive compulsive disorder, post-traumatic stress disorder, bipolar disorder, anxiety disorder, or active suicidal tendency; other clinically important medical conditions as determined by the investigators; or any other unstable medical condition such as cardiovascular disease were excluded. [source, 2016]
In the present study, it was seen that Desvenlafaxine produced a decrease from the baseline value of HAM-D from 3 weeks onward till the end of the study, that is, at 6 weeks. [source, 2016]